First, a selective CDK2 inhibitor would allow for the sole targeting of CDK2 in cancers where CDK2 is thought to be the primary driver (e.g., CCNE1-amplified tumors), avoiding the concomitant (and potentially dose-limiting) toxicity of inhibiting CDKs 4 and 6. Here, CCNE1 is linked to cancer.